AstraZeneca enters licensing agreement with China Medical System Holdings for hypertension medicine

AstraZeneca today announced it has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for the commercialisation rights in China to its calcium channel blocker, Plendil (felodipine). Plendil was first approved in China in 1995 for the treatment of hypertension or high blood pressure and in 2015 achieved Product Sales of $189 million.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Related Links:

HIGH blood pressure means a person's blood pressure is consistently too high and dangerous consequences could ensue. With many on lock down and self-isolating, how can you properly measure your blood pressure without the equipment?
Source: Daily Express - Health - Category: Consumer Health News Source Type: news
Conditions:   Persistent Fetal Circulation;   Persistent Pulmonary Hypertension of the Newborn;   PPHN Interventions:   Drug: Nebulized Magnesium Sulfate;   Drug: Intravenous Magnesium Sulfate Sponsor:   Sohag University Completed
Source: - Category: Research Source Type: clinical trials
Conditions:   Periodontal Diseases;   Gingivitis;   Hypertension Interventions:   Behavioral: electric toothbrush;   Procedure: Professional oral hygiene Sponsor:   University of L'Aquila Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Polycystic Ovary Syndrome;   Hypertension Interventions:   Drug: GnRH antagonist;   Drug: GnRH antagonist + MethylTESTOSTERone 5 MG Sponsor:   Yale University Enrolling by invitation
Source: - Category: Research Source Type: clinical trials
This study was designed to investigate the role of long non-coding RNA (lncRNA) metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) in the proliferation as well as apoptosis of human umbilical vein endothelial cells (HUVECs), to offer a basis for therapy of hypertension. MATERIAL AND METHODS The lncRNA MALAT1 expression, hsa-miR-124-3p, hsa-miR-135a-5p, hsa-miR-135b-5p, and hsa-miR-455-5p in plasma were measured from 230 patients with hypertension and 230 non-hypertensive controls. The mechanism for lncRNA MALAT1 modulating the proliferation and apoptosis of HUVECs was explored by cell transfection, Cell Counti...
Source: Medical Science Monitor - Category: Research Tags: Med Sci Monit Source Type: research
A better understanding of how hypertension control differs between population subgroups may help improve management and reduce disparities.American Journal of Epidemiology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
We describe the use of the Impella 5.0 (Abiomed Inc., Danvers, Massachusetts) as a bridge to HeartMate 3 implantation in a highly sensitized patient with severe pulmonary hypertension following the Mustard procedure for TGA.
Source: ASAIO Journal - Category: Medical Devices Tags: Case Report Source Type: research
No abstract available
Source: ASAIO Journal - Category: Medical Devices Tags: Letters to the Editor Source Type: research
This study aimed to assess the hemodynamic effects of concomitant MVS. Of all 73 enrolled patients, 44 patients had undergone concomitant MVS and 29 patients had not. Before LVAD implantation, MVS group had higher pulmonary capillary wedge pressure (p = 0.04). After LVAD implantation, MVS group had higher mean pulmonary artery pressure and cardiac output (CO). During the hemodynamic ramp study, MVS group had steeper CO slopes (0.18 [0.13 0.28] vs. 0.15 [0.08, 0.20] L/min/step; p = 0.04) at incremental LVAD speed and achieved a higher CO at the optimized set speed (5.5 [4.7, 6.9] vs. 4.9 [4.0, 5.7] L/min; p = 0.03). One-yea...
Source: ASAIO Journal - Category: Medical Devices Tags: Adult Circulatory Support Source Type: research
Children with end-stage lung failure awaiting lung transplant would benefit from improvements in artificial lung technology allowing for wearable pulmonary support as a bridge-to-transplant therapy. In this work, we designed, fabricated, and tested the Pediatric MLung—a dual-inlet hollow fiber artificial lung based on concentric gating, which has a rated flow of 1 L/min, and a pressure drop of 25 mm Hg at rated flow. This device and future iterations of the current design are designed to relieve pulmonary arterial hypertension, provide pulmonary support, reduce ventilator-associated injury, and allow for more effecti...
Source: ASAIO Journal - Category: Medical Devices Tags: Biomedical Engineering Source Type: research
More News: AstraZeneca | Calcium | Felodipine | Hypertension | Pharmaceuticals